Quest PharmaTech Announces Results from AGM
12 October 2024 - 8:00AM
Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today
announced the results of its October 8, 2024 annual general meeting
of shareholders.
The Company announces the following four
directors have been elected to the Company’s Board of
Directors:
J. Mark Lievonen, C.M., FCPA, FCA, LLD Jeffrey
Shon, J. DBradley J. Glass J.DMadi R. Madiyalakan, Ph.D.
At the meeting, shareholders reappointed the
Company’s auditors, Kingston Ross Pasnak, LLP.
“I would like to thank all of our Board members
for their service to the Company,” said Dr. Madi R. Madiyalakan,
Chief Executive Officer of Quest. “I am confident that Quest’s
Board of Directors will be able to help the Company execute its
business strategy to add value to our shareholders.”
Approximately 75,392,253 shares were voted for
the Company’s shareholder meeting representing approximately 44.58%
of the Company’s shares eligible to vote.
On a corporate matter, Quest announces the
granting of 1,800,000 stock options to Directors and Officers, all
at a volume weighted average exercise price of $0.05 per common
share, expiring 10 years from the date of grant, subject to TSX
Venture Exchange approval.
About Quest PharmaTech Inc.
Quest PharmaTech Inc is a publicly traded,
Canadian based biopharmaceutical company (QPT: TSX-V) developing
products to improve the quality of life through investee companies
and proprietary technologies. Quest is developing the proprietary
MAb-AR9.6 targeting MUC16 as theranostic agents for cancer.
MAb-AR9.6 was licensed from the University of Nebraska Medical
Centre and currently is in late preclinical stage development. The
Company also has a 42.5% ownership interest in OncoQuest Inc. which
sold its immunotherapy technology assets to Korea-based Dual
Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership
interest in OncoVent, a Chinese joint venture developing
antibody-based immunotherapeutic products for cancer for the
Greater China territory. To learn more, visit
www.questpharmatech.com.
Forward Looking Statements
Statements on the development and potential of
the Company’s MAb AR9.6 product candidate constitute
forward-looking statements. Such statements are based on the
current expectations of management and inherently involve numerous
risks and uncertainties, known and unknown, many of which are
beyond Quest’s control. These risks include the achievement of
forecasted development milestones, that actual results may vary
once the final and quality-controlled verification of data and
analyses has been completed and other risks disclosed in the
Company’s Management’s Discussion & Analysis and other public
fillings at www.sedarplus.ca. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue
reliance, if any, on any forward-looking statements included in
this news release. These statements speak only as of the date made
and Quest is under no obligation and has no intention to update or
revise such statements as a result of any event, circumstances or
otherwise, unless required by applicable law.
For further information:
Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech
Inc.Tel: (780) 448-1400, Email: madi@questpharmatech.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Quest PharmaTech (TSXV:QPT)
Historical Stock Chart
From Nov 2024 to Dec 2024
Quest PharmaTech (TSXV:QPT)
Historical Stock Chart
From Dec 2023 to Dec 2024